Overview

The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function.

Status:
Terminated
Trial end date:
2020-03-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate how dapagliflozin mechanism of action is impacted by Type 2 Diabetes Mellitus status and kidney function
Phase:
Phase 4
Details
Lead Sponsor:
AstraZeneca
Treatments:
Dapagliflozin